EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers

William Jacot iD, Marie-Christine Chateau, Simon Thezenas, Séverine Guiu, Nelly Firmin, Virginie Lafont, Gwendal Lazennec, Charles Theillet iD, Florence Boissière-Michot

Cancer Medicine · 2025

DOI: 10.1002/cam4.70615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von William Jacot und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antigens, Neoplasm, Biomarkers, Tumor, Cell Adhesion Molecules. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo, inc, Daiichi Sankyo Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Triple‐Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype, in which targeting the Trophoblast cell‐surface antigen‐2 (Trop‐2), using antibody‐drug conjugates (ADC), results in significant clinical improvement. However, clinicopathological correlations with Trop‐2 protein expression levels remain limited in TNBC patients.

Methods

Here we assessed by immunohistochemistry (IHC) using the mouse monoclonal anti‐Trop‐2 antibody (Enzo, Cat. ENZ‐ABS380) cell membrane Trop‐2 expression levels and classified them in 3 H‐Score classes, low (< 100), moderate (100–200), and strong (> 200). We also evaluated potential associations with clinicopathological variables including basal‐like and molecular apocrine phenotypes, immune infiltrate characteristics, PTEN and PIK3CA alterations in a large retrospective series of 228 nonmetastatic TNBC patients.

Results

Trop‐2 expression was evaluated as low, moderate and strong in 12.3%, 28.9%, and 58.8% of the cases respectively. Only 3 tumors showed no Trop‐2 expression. Interestingly, Trop‐2 expression was not associated with classical breast cancer clinicopathological variables, HER2 levels or molecular subtype, neither did we observe an association with relapse‐free survival. Only a marginal association with pT1 tumors was observed, which tended to express increased levels of Trop‐2 protein. In order to determine possible fluctuations of Trop‐2 protein expression levels during the course of the disease, we studied a second independent cohort of 18 TNBC comprised of serial tissue samples (diagnostic biopsies, surgical resection specimens and corresponding patients‐derived xenografts (PDX)). Trop‐2 levels remained globally stable between cognate tumor samples with only one exception corresponding to a Trop‐2‐negative tumor giving rise to a Trop‐2‐positive PDX.

Conclusions

As Trop‐2 expression appears nearly constant and independent of classical TNBC variables and outcome, association of anti‐Trop‐2 therapies with other targeted therapies can be evaluated without reducing the population in specific TNBC subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesHumansFemalePrognosisMiddle AgedAdultAgedRetrospective StudiesImmunohistochemistryAged, 80 and over

Stichwörter der Autor:innen

Trop‐2basal‐likeexpressionmolecular apocrineprognosistriple‐negative breast cancer

Substanzen

Antigens, NeoplasmTACSTD2 protein, humanBiomarkers, TumorCell Adhesion Molecules

Autor:innen und Institutionen

  • Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.
  • Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.
  • Montpellier University, Montpellier, France.
  • Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, France.
  • Biometrics Unit, Institut du Cancer Montpellier (ICM), Université de Montpellier, Montpellier, France.
  • Institut du Cancer Montpellier (ICM), Université de Montpellier, Montpellier, France.

ORCID-Profile: William Jacot, Charles Theillet

Förderung

  • Daiichi Sankyo, inc
  • Daiichi Sankyo Europe

Zitieren

APA

Jacot, W., Chateau, M. C., Thezenas, S., Guiu, S., Firmin, N., Lafont, V., Lazennec, G., Theillet, C., & Boissière-Michot, F. (2025). Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers. Cancer Medicine. https://doi.org/10.1002/cam4.70615

Vancouver

Jacot W, Chateau MC, Thezenas S, Guiu S, Firmin N, Lafont V, et al. Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers. Cancer Medicine. 2025. doi:10.1002/cam4.70615

BibTeX
@article{Jacot2025,
  author = {Jacot, William and Chateau, Marie-Christine and Thezenas, Simon and Guiu, Séverine and Firmin, Nelly and Lafont, Virginie and Lazennec, Gwendal and Theillet, Charles and Boissière-Michot, Florence},
  title = {Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70615}
}
Kostenlos starten →